Connect with us

Life Sciences

Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder

–Topline efficacy data expected in Q4 2023 – – Preparations are underway to scale the CYB003 program to a potential...